FRI0305 PREDICTIVE VALUE OF INNATE LYMPHOID CELLS IN SYSTEMIC SCLEROSIS. (June 2019)

• Record Type: Journal Article
• Authors: Soare, Alina; Weber, Stefanie; Luber, Markus; Rauber, Simon; Wohlfahrt, Thomas; Schett, Georg; Distler, Jörg; Ramming, Andreas
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 834
• Page End: 834
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.7639
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Activation of the immune system is a characteristic feature of SSc. Numerous studies have suggested that type 2 and type 3 cytokines are key drivers of progressive fibrosis. Recently, innate lymphoid cells (ILC) are emerging as an important cellular source of type 2 and type 3 cytokines triggering fibrotic tissue remodeling independently of the adaptive immune system. ILCs are characterized by the absence of conventional lineage markers. Similar to T cells, they are categorized into three groups (ILC1, ILC2, ILC3), according to distinct pattern of cytokine production and the requirement of specific transcription factors guiding their development and function. Increased levels of ILC2 were found in patients with SSc. However, the contributive role of ILC2 and ILC3 in pathogenesis of SSc is not completely understood. Objectives: We aim in our study to evaluate the predictive role of ILC2 and ILC3 in SSc patients. Methods: We conducted an observational retrospective study on 52 patients with SSc fulfilling the 2013 ACR/EULAR classification criteria. Yearly clinical, laboratory and investigational data according to EUSTAR recommendations were collected. Blood samples collected between 15.09.2014 and 15.01.2015 were analyzed by flow cytometry and ILC2 and ILC3 counts were measured. The predictive value of ILC2 and ILC3 during a 2-year follow-up was analyzed using SPSS 21.0. ILC3 counts were also analyzed in skin sections (10 patients with SSc and 10 healthy controls) by immunofluorescence (IF) staining using two complementary panels of markers. Cytokine production of skin resident ILC3s was additionally analyzed by IF staining. Results: 52 patients were included in the study, 78% female, 63% limited cutaneous SSc with a mean follow-up time of 2.85 ± 1.28 years. At baseline we have shown that circulating ILC2s are significantly increased compared to gender and age-matched healthy controls. Increased numbers of ILC2s significantly correlated with worsening of mRSS calculated by five point increase in mRSS or 25% increase from baseline (p < 0.001; 95% CI 1.39 – 3.26). ILC2 counts also correlated with 5% decrease of diffusion capacity of carbon monoxide (DLCO) during the follow-up time (p < 0.0001; 95% CI 1.83 – 3.49). Worsening of forced vital capacity (FVC) assessed as 5% decrease over 2 years was also significantly correlated with an increased number of ILC2s (p < 0.0001; 95% CI 1.27 – 3.04). In contrast, we did not find any correlation regarding increase in pulmonary arterial pressure assessed by echocardiography. Although new appearance of digital ulcers could not be predicted by ILC2 counts, increased numbers of ILC2s were correlated with digital ulcers at follow-up. ILC2s did not have a predictive value for death during the follow-up time. In contrast to ILC2, circulating ILC3s were not found to be correlated with worsening of disease activity. However, ILC3s were prominent in fibrotic skin of SSc patients compared to healthy controls, and showed strong production of IL-17. Conclusion: Here, we provide first evidence for a role of ILC2s as potential prognostic marker of disease progression in SSc. Circulating ILC3 counts were not elevated in SSc. However, ILC3s showed strong cytokine production in the fibrotic skin of SSc patients. The functional impact has to be further evaluated. Disclosure of Interests: Alina Soare: None declared, Stefanie Weber: None declared, Markus Luber: None declared, Simon Rauber: None declared, Thomas Wohlfahrt: None declared, Georg Schett: None declared, Jörg Distler: None declared, Andreas Ramming Grant/research support from: Novartis